Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.51 USD | -0.79% | +2.87% | +13.57% |
25/04 | Sector Update: Health Care Stocks Decline Late Afternoon | MT |
25/04 | Sector Update: Health Care | MT |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+13.57% | 960M | C- | ||
+7.84% | 218B | B | ||
+7.35% | 184B | B- | ||
+13.04% | 135B | B- | ||
-1.33% | 62.38B | A- | ||
+11.80% | 51.37B | B+ | ||
+4.81% | 50.9B | B+ | ||
+0.30% | 40.87B | A | ||
+2.78% | 36.28B | - | ||
+26.14% | 31.88B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- LAB Stock
- Ratings Standard BioTools Inc.